Diagonal Therapeutics, a Cambridge, MA-based biotechnology company developing new approach to discovering agonist antibodies, raised $128M in funding.
The round was co-led by BVF Partners and Atlas Venture, with participation from Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, Velosity Capital, and Checkpoint Capital.
The company intends to use the funds for further advancement of its proprietary platform and pipeline of novel therapeutics to value-creating milestones, including its lead program for the treatment of hereditary hemorrhagic telangiectasia (HHT), a severely debilitating bleeding disorder with limited therapeutic options, through clinical proof-of-concept.
Diagonal Therapeutics leverages a platform that combines proprietary computational and experimental techniques to overcome challenges associated with agonist antibody drug discovery. Diagonal’s emerging pipeline – discovered using the platform – has the potential to deliver therapies to patients by tackling the underlying cause of disease.
Using the platform, Diagonal has discovered antibody candidates against four complex targets, providing a new path to treating severe diseases, including:
- Hereditary hemorrhagic telangiectasia (HHT)
- Pulmonary arterial hypertension (PAH)
FinSMEs
04/04/2024